NeuroPace reported second quarter 2026 financial results with total revenue of $22.8 million, a 17% increase from the prior year period. RNS System revenue reached $22.5 million, reflecting 21.3% growth. The company posted a GAAP net loss of $6.2 million and an adjusted EBITDA loss of $2.8 million, both improvements over the previous year's figures. Management raised full-year 2026 total revenue guidance to between $99.5 million and $101.5 million, citing expected service revenue growth and sustained core business momentum. The company also launched its ECoG Assistant AI tool and reported positive clinical data from the NAUTILUS trial for idiopathic generalized epilepsy. NeuroPace operates in the medical device industry, specializing in brain-responsive neurostimulation systems for treating drug-resistant epilepsy.

NeuroPace, Inc. announced on July 28, 2026, that the U.S. Food and Drug Administration (FDA) issued a not approvable letter for its Premarket Approval Supplement (PMA-S) seeking to expand the RNS System indication to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures. The FDA requested additional clinical evidence, specifically data from the NAUTILUS trial and supporting literature, before the submission can be approved. NeuroPace intends to submit a Submission Issue Request to discuss the path forward and continue collaborating with the FDA. The company reported that 18-month NAUTILUS results showed a 77% median reduction in GTC seizures, with 40% of patients achieving seizure freedom. NeuroPace operates in the medical device industry, developing the RNS System for the treatment of drug-resistant epilepsy.

NeuroPace, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where stockholders elected Class II directors Lisa Andrade and Scott Huennekens. Additionally, stockholders ratified the proposals to appoint PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year 2026.